Literature DB >> 15020081

CD4 T cell activation and disease activity at onset of multiple sclerosis.

J Jensen1, A R Langkilde, C Fenst, M S Nicolaisen, H G Roed, M Christiansen, F Sellebjerg.   

Abstract

We studied CD4 T cell activation in patients with clinically isolated syndromes (CIS) suggesting an initial attack of multiple sclerosis. The percentage of blood CD26+ CD4 T cells was increased in these patients, and correlated with magnetic resonance imaging disease activity and clinical disease severity. In contrast, the percentage of CD25+ CD4 T cells in cerebrospinal fluid correlated negatively with the cerebrospinal fluid concentration of myelin basic protein and the presence of IgG oligoclonal bands. These results suggest that distinct systemic and intrathecal T cell activation states correlate with disease activity and risk of subsequently developing MS in CIS patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15020081     DOI: 10.1016/j.jneuroim.2003.12.019

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  9 in total

1.  PRMT5-Selective Inhibitors Suppress Inflammatory T Cell Responses and Experimental Autoimmune Encephalomyelitis.

Authors:  Lindsay M Webb; Stephanie A Amici; Kyle A Jablonski; Himanshu Savardekar; Amanda R Panfil; Linsen Li; Wei Zhou; Kevin Peine; Vrajesh Karkhanis; Eric M Bachelder; Kristy M Ainslie; Patrick L Green; Chenglong Li; Robert A Baiocchi; Mireia Guerau-de-Arellano
Journal:  J Immunol       Date:  2017-01-13       Impact factor: 5.422

Review 2.  Potential disease biomarkers: dipeptidyl peptidase 4 and fibroblast activation protein.

Authors:  Roger Yazbeck; Simone E Jaenisch; Catherine A Abbott
Journal:  Protoplasma       Date:  2017-06-16       Impact factor: 3.356

3.  The type of responder T-cell has a significant impact in a human in vitro suppression assay.

Authors:  Srikanta Jana; Hope Campbell; Jeffrey Woodliff; Jill Waukau; Parthav Jailwala; Jugal Ghorai; Soumitra Ghosh; Sanja Glisic
Journal:  PLoS One       Date:  2010-12-03       Impact factor: 3.240

4.  Endogenous and recombinant type I interferons and disease activity in multiple sclerosis.

Authors:  Finn Sellebjerg; Martin Krakauer; Signe Limborg; Dan Hesse; Henrik Lund; Annika Langkilde; Helle Bach Søndergaard; Per Soelberg Sørensen
Journal:  PLoS One       Date:  2012-06-06       Impact factor: 3.240

Review 5.  Are cerebrospinal fluid biomarkers useful in predicting the prognosis of multiple sclerosis patients?

Authors:  Alberto Gajofatto; Matilde Bongianni; Gianluigi Zanusso; Maria Donata Benedetti; Salvatore Monaco
Journal:  Int J Mol Sci       Date:  2011-11-16       Impact factor: 5.923

6.  NF-κB/mTOR/MYC Axis Drives PRMT5 Protein Induction After T Cell Activation via Transcriptional and Non-transcriptional Mechanisms.

Authors:  Lindsay M Webb; Janiret Narvaez Miranda; Stephanie A Amici; Shouvonik Sengupta; Gregory Nagy; Mireia Guerau-de-Arellano
Journal:  Front Immunol       Date:  2019-03-19       Impact factor: 7.561

7.  Exploring the Mechanism of Yiqi Qingre Ziyin Method in Regulating Neuropeptide Expression for the Treatment of Atrophic Rhinitis.

Authors:  Lixing Lu; Xueran Kang; Bin Yi; Chenyan Jiang; Xiaojun Yan; Bin Chen; Yuxing Sun; Fangze Shi; Yuanbo Luo; Yisheng Chen; Runjie Shi
Journal:  Dis Markers       Date:  2022-03-08       Impact factor: 3.434

8.  Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis.

Authors:  Lars Börnsen; Jeppe Romme Christensen; Rikke Ratzer; Annette Bang Oturai; Per Soelberg Sørensen; Helle Bach Søndergaard; Finn Sellebjerg
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

9.  PRMT5 Promotes Cyclin E1 and Cell Cycle Progression in CD4 Th1 Cells and Correlates With EAE Severity.

Authors:  Stephanie A Amici; Wissam Osman; Mireia Guerau-de-Arellano
Journal:  Front Immunol       Date:  2021-06-08       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.